Advertisement

Current Cardiology Reports

, 13:544 | Cite as

The Role of Triglycerides in Atherosclerosis

  • Beatriz G. TalayeroEmail author
  • Frank M. Sacks
Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor)

Abstract

Hypertriglyceridemia is a prevalent risk factor for cardiovascular disease (CVD) and increasingly important in the setting of current obesity and insulin resistance epidemics. High triglyceride (TG) levels are markers for several types of atherogenic lipoproteins. Patients who have hypertriglyceridemia may be at significant risk for CVD even if low-density lipoprotein cholesterol levels are at goal, and therefore warrant treatment that optimizes diet, reduces overweight, and promotes regular exercise. High-risk patients with hypertriglyceridemia, such as those with diabetes, CVD, or metabolic syndrome, may benefit from additional drug treatment aside from a statin to address other lipid abnormalities. In this discussion, we review the role of hypertriglyceridemia and its associated atherogenic lipoproteins in the pathogenesis of atherosclerosis, the relevance of a high TG level as a predictor of CVD, the cardiovascular outcomes from TG-lowering intervention trials, and the current guidelines for treating hypertriglyceridemia.

Keywords

Atherogenic dyslipidemia Atherogenic remnant lipoproteins Atherosclerosis Cardiovascular disease Chylomicron remnants Lipoprotein lipase Risk factor Triglycerides Triglyceride-rich lipoproteins Very low density lipoproteins 

Clinical Trial Acronyms

ACCORD

Action to Control Cardiovascular Risk in Diabetes

AIM-HIGH

Atherothrombosis Intervention in Metabolic syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes

JELIS

Japan EPA Lipid Intervention Study

NCEP ATP III

National Cholesterol Education Program Adult Treatment Panel III

NHANES

National Health and Nutrition Examination Survey

PROVE IT-TIMI 22

Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22

Notes

Disclosure

Conflicts of interest: B.G. Talayero: none; F.M. Sacks: has board membership with R3i Foundation; has been a consultant for Abbott, Amgen, Pfizer, Roche, Merck, Eli Lilly, ISIS, and Genzyme; has given expert testimony for Abbott and Par; has received grant support from ISIS; and has received honoraria from Abbott.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.PubMedCrossRefGoogle Scholar
  2. 2.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106(25):3143–421.Google Scholar
  3. 3.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Schulte H, Cullen P, Assmann G. Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis. 1999;144(1):199–209.PubMedCrossRefGoogle Scholar
  7. 7.
    Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.PubMedCrossRefGoogle Scholar
  9. 9.
    Brewer Jr HB. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83(9B):3F–12F.PubMedCrossRefGoogle Scholar
  10. 10.
    Gianturco SH, Ramprasad MP, Song R, et al. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol. 1998;18(6):968–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Botham KM, Moore EH, De Pascale C, et al. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans. 2007;35:454–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Ooi EM, Barrett PH, Chan DC, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114(10):611–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Zheng C, Furtado J, Khoo C, et al. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation. 2010;121(15):1722–34. These results support a central role for apo C-III in metabolic defects leading to hypertriglyceridemia and the dense LDL phenotype. In hypertriglyceridemia, TG-rich lipoprotein metabolism shifts from an apo E–dominated system to an apo C-III–dominated system characterized by reduced clearance of TG-rich lipoproteins and their conversion to dense LDL.PubMedCrossRefGoogle Scholar
  14. 14.
    Kamagate A, Dong HH. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle. 2008;7(20):3162–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997;38(11):2173–92.PubMedGoogle Scholar
  16. 16.
    Colhoun HM, Otvos JD, Rubens MB, et al. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes. 2002;51(6):1949–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Van Eck M, Zimmermann R, Groot PH, et al. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20(9):E53–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial function. Circulation. 2008;118(7):731–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res. 2009;50(2):204–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Palmer AM, Murphy N, Graham A. Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis. 2004;173(1):27–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Patel S, Puranik R, Nakhla S, et al. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis. 2009;204(1):424–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114(7):681–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Hiukka A, Stahlman M, Pettersson C, et al. ApoCIII-Enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 2009;58(9):2018–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Zheng C, Murdoch S, Brunzell J, et al. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol. 2006;26(4):891–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37(4):693–707.PubMedGoogle Scholar
  27. 27.
    Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 2010;21:409–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Wehinger A, Tancevski I, Schgoer W, et al. Phospholipid transfer protein augments apoptosis in THP-1-derived macrophages induced by lipolyzed hypertriglyceridemic plasma. Arterioscler Thromb Vasc Biol. 2007;27:908–15.PubMedCrossRefGoogle Scholar
  29. 29.
    Georgieva AM, Cate HT, Keulen ET, et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis. 2004;75(2):345–51.CrossRefGoogle Scholar
  30. 30.
    Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2(2):82–104.PubMedCrossRefGoogle Scholar
  31. 31.
    Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2007;193:321–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Jacobs DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982;116:878–85.PubMedGoogle Scholar
  33. 33.
    Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–86.CrossRefGoogle Scholar
  34. 34.
    Di Angelantonio E, Sarwar N, Perry P, et al. Emerging risk factors collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.PubMedCrossRefGoogle Scholar
  35. 35.
    • Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757–63. This study highlights a strong and synergistic contribution of high TG and low HDL-C levels to CHD when LDL-C is at goal. These results suggest that lowering TGs may have greater potential for clinical benefit when LDL-C is low.PubMedCrossRefGoogle Scholar
  36. 36.
    • Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case–control study. Diab Vasc Dis Res. 2010;7(3):204–12. Findings from this study suggest that residual cardiovascular risk associated with hypertriglyceridemia is greatest in persons in whom LDL-C concentration is in a low target range.PubMedCrossRefGoogle Scholar
  37. 37.
    Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the american heart association. Circulation. 2011;123:2292–333.PubMedCrossRefGoogle Scholar
  40. 40.
    Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.PubMedCrossRefGoogle Scholar
  41. 41.
    Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–16.PubMedCrossRefGoogle Scholar
  42. 42.
    Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008;101:1003–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259(5):481–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Sniderman A, Williams K, Cobbaert C. ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep. 2009;11:358–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247–58.PubMedCrossRefGoogle Scholar
  47. 47.
    Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B–9B.PubMedCrossRefGoogle Scholar
  48. 48.
    Sacks FM, Alaupovic P, Moye LA. Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. Am J Cardiol. 2002;90(2):165–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Girman CJ, Rhodes T, Mercuri M, et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997;20:1048]. Diabetes Care. 1997;20:614–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–92.PubMedGoogle Scholar
  52. 52.
    Kastelein JJP, van der Stieg W, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Pfeffer MA, Sacks FM, Moyé LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial: cholesterol and recurrent events. J Am Coll Cardiol. 1999;33:125–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The ACCORD Study Group. N Engl J Med. 2010;362:1563–74.PubMedCrossRefGoogle Scholar
  55. 55.
    Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–8.PubMedCrossRefGoogle Scholar
  56. 56.
    The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–7.Google Scholar
  57. 57.
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37–45.PubMedGoogle Scholar
  58. 58.
    Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–91.PubMedCrossRefGoogle Scholar
  59. 59.
    Tenkanen L, Mantarri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779–85.PubMedGoogle Scholar
  60. 60.
    Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162:2597–604.PubMedCrossRefGoogle Scholar
  61. 61.
    Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Scott R, d’Emden M, Best J, et al. (on behalf of the FIELD Investigators).: Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation. 2007;116:II_838. Abstract 3691.Google Scholar
  63. 63.
    Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692. author reply 694–5. Meta-analysis of the major clinical trials of fibrate treatment found that fibrates reduced CHD events among patients with hypertriglyceridemia and low HDL-C.PubMedCrossRefGoogle Scholar
  64. 64.
    • Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–84. This reference is important because it reviews inconsistent findings from several clinical trials regarding the effect of fibrates on cardiovascular risk concluding that fibrates can reduce the risk of major coronary events, and might have a role in individuals at high risk of cardiovascular events and in those with combined dyslipidemia.PubMedCrossRefGoogle Scholar
  65. 65.
    Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:20B–6B.PubMedCrossRefGoogle Scholar
  66. 66.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81.CrossRefGoogle Scholar
  67. 67.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.PubMedCrossRefGoogle Scholar
  68. 68.
    AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011;161(3):471–7.CrossRefGoogle Scholar
  69. 69.
    Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24.PubMedCrossRefGoogle Scholar
  70. 70.
    Balk E, Chung M, Lichtenstein A, et al. Effects of Omega-3 Fatty Acids on CardiovascularRisk Factors and Intermediate Markers of Cardiovascular Disease. Evidence Report/Technology Assessment No. 93 (prepared byTufts-New England Medical Center Evidence-Based Practice Center under contract No. 290-02-0022). AHRQ publication No. 04-E010-2. Rockville, MD: Agency for Healthcare Research and Quality; 2004.Google Scholar
  71. 71.
    Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in Circulation 2003,107:512]. Circulation. 2002;106:2747–57.PubMedCrossRefGoogle Scholar
  72. 72.
    Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365–72.PubMedCrossRefGoogle Scholar
  73. 73.
    Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.PubMedCrossRefGoogle Scholar
  75. 75.
    Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.PubMedCrossRefGoogle Scholar
  76. 76.
    Appel LJ, Sacks FM, Carey VJ, OmniHeart Collaborative Research Group, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294:2455–64.PubMedCrossRefGoogle Scholar
  77. 77.
    Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins and exercise. J Cardiopulm Rehabil. 2002;22:385–98.PubMedCrossRefGoogle Scholar
  78. 78.
    Fruchart JC, Sacks FM, Hermans MP, et al. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319–35.PubMedCrossRefGoogle Scholar
  79. 79.
    Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes: a systematic review. Obes Rev. 2004;5:43–50.PubMedCrossRefGoogle Scholar
  80. 80.
    Brown B, Canner PL, McGovern ME, et al. Nicotinic acid. In: Ballantyne C, editor. Clinical lipidology, a companion to braunwald’s heart disease. Philadelphia: Saunders; 2009. p. 298–314.Google Scholar
  81. 81.
    Jones PH. Fibrates. In: Ballantyne C, editor. Clinical lipidology, a companion to braunwald’s heart disease. Philadelphia: Saunders; 2009. p. 315–25.Google Scholar
  82. 82.
    Harris WS, Jacobson TA. Omega-3 fatty acids. In: Ballantyne C, editor. Clinical lipidology, a companion to braunwald’s heart disease. Philadelphia: Saunders; 2009. p. 326–38.Google Scholar
  83. 83.
    Fontana L, Villareal DT, Weiss EP, the Washington University School of Medicine CALERIE Group, et al. Calorie restriction or exercise: effects on coronary heart disease risk factors: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2007;293:E197–202.PubMedCrossRefGoogle Scholar
  84. 84.
    Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of NutritionHarvard School of Public HealthBostonUSA
  2. 2.Department of MedicineHarvard Medical SchoolBostonUSA
  3. 3.Cardiovascular MedicineBrigham & Women’s HospitalBostonUSA

Personalised recommendations